Inimmune

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics. Inimmune was founded in early 2016 by Drs. Inimmune was formed from an experienced, close-knit team of biotech/pharmaceutical industry professionals. Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Our goal at Inimmune is to recruit, hire, and maintain a diverse workforce. At Inimmune our team is advancing the next generation of immunotherapies and vaccine technology for the benefit of human kind. The group has extensive expertise in synthetic and process chemistry, drug formulation, and immunology. Our pipeline includes innovative new treatments to harness the innate immune system in areas of critical patient need such as oncology, allergic rhinitis, food allergy, infectious disease vaccines, and novel antibiotics for bacterial infections.